GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adlai Nortye Ltd (NAS:ANL) » Definitions » Insider Ownership

ANL (Adlai Nortye) Insider Ownership : 0.00 % (As of Apr. 13, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Adlai Nortye Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Adlai Nortye's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Adlai Nortye's Institutional Ownership is 0.15%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Adlai Nortye's Float Percentage Of Total Shares Outstanding is 83.86%.


Adlai Nortye Insider Ownership Historical Data

The historical data trend for Adlai Nortye's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adlai Nortye Insider Ownership Chart

Adlai Nortye Annual Data
Trend Dec21 Dec22 Dec23
Insider Ownership
- - -

Adlai Nortye Quarterly Data
Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23 Jun24
Insider Ownership Get a 7-Day Free Trial - - - - -

Adlai Nortye Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Adlai Nortye Business Description

Traded in Other Exchanges
N/A
Address
685 US Highway 1, New Jersey Biotechnology Development Center, 2nd floor, North Brunswick, NJ, USA, 08902
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.